PL2936151T3 - Sposoby leczenia i/lub ograniczania rozwoju cukrzycy - Google Patents

Sposoby leczenia i/lub ograniczania rozwoju cukrzycy

Info

Publication number
PL2936151T3
PL2936151T3 PL13811451T PL13811451T PL2936151T3 PL 2936151 T3 PL2936151 T3 PL 2936151T3 PL 13811451 T PL13811451 T PL 13811451T PL 13811451 T PL13811451 T PL 13811451T PL 2936151 T3 PL2936151 T3 PL 2936151T3
Authority
PL
Poland
Prior art keywords
diabetes
treating
methods
limiting development
development
Prior art date
Application number
PL13811451T
Other languages
English (en)
Inventor
Per Olof Berggren
Shao-Nian YANG
Original Assignee
Biocrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocrine Ab filed Critical Biocrine Ab
Publication of PL2936151T3 publication Critical patent/PL2936151T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL13811451T 2012-12-18 2013-12-17 Sposoby leczenia i/lub ograniczania rozwoju cukrzycy PL2936151T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738835P 2012-12-18 2012-12-18
PCT/EP2013/076917 WO2014095875A1 (en) 2012-12-18 2013-12-17 Methods for treating and/or limiting development of diabetes
EP13811451.7A EP2936151B1 (en) 2012-12-18 2013-12-17 Methods for treating and/or limiting development of diabetes

Publications (1)

Publication Number Publication Date
PL2936151T3 true PL2936151T3 (pl) 2018-11-30

Family

ID=49876594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13811451T PL2936151T3 (pl) 2012-12-18 2013-12-17 Sposoby leczenia i/lub ograniczania rozwoju cukrzycy

Country Status (9)

Country Link
US (1) US9068971B2 (pl)
EP (1) EP2936151B1 (pl)
JP (1) JP6322209B2 (pl)
KR (1) KR102141898B1 (pl)
CN (1) CN105051534B (pl)
DK (1) DK2936151T3 (pl)
ES (1) ES2689922T3 (pl)
PL (1) PL2936151T3 (pl)
WO (1) WO2014095875A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170115035A (ko) 2015-02-09 2017-10-16 바이오크린 에이비 근위축성 측색 경화증을 가진 대상체에서 당뇨병을 치료하고/하거나 당뇨병의 발병을 제한하는 방법
CA2996064C (en) * 2015-08-18 2024-02-13 Novation Pharmaceuticals Inc. Benzopyran derivatives and uses thereof
WO2017095725A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017095724A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
EP4209783A1 (en) 2016-12-02 2023-07-12 Sophion Bioscience A/S Seal enhancer
CN113967210B (zh) * 2020-07-24 2025-02-07 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
JP2002080499A (ja) * 2000-09-01 2002-03-19 Suntory Ltd カルシウムチャンネル阻害作用を有する新規ペプチド
US20040171073A1 (en) 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
ATE409046T1 (de) * 2003-03-12 2008-10-15 Rappaport Family Inst For Res Zusammensetzungen und verfahren zur diagnose und behandlung einer entzündung
EP1623228B1 (en) * 2003-04-29 2012-12-05 BioCrine AB Apociii and the treatment and diagnosis of diabetes
EP3549594A1 (en) * 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
WO2009128734A1 (en) * 2008-04-18 2009-10-22 Vialactia Biosciences (Nz) Limited Marker assisted identification of mammals for desired phenotypic trait
US8557513B2 (en) 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes

Also Published As

Publication number Publication date
JP6322209B2 (ja) 2018-05-09
ES2689922T3 (es) 2018-11-16
US9068971B2 (en) 2015-06-30
US20140170113A1 (en) 2014-06-19
HK1214355A1 (en) 2016-07-22
EP2936151B1 (en) 2018-07-18
EP2936151A1 (en) 2015-10-28
WO2014095875A1 (en) 2014-06-26
JP2016510210A (ja) 2016-04-07
CN105051534B (zh) 2017-08-18
KR20150096676A (ko) 2015-08-25
CN105051534A (zh) 2015-11-11
KR102141898B1 (ko) 2020-08-06
DK2936151T3 (en) 2018-08-27

Similar Documents

Publication Publication Date Title
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
SG11201504049VA (en) Compounds and their methods of use
EP2890391A4 (en) METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA
IL237528B (en) Methods for preventing and treating preeclampsia
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
GB201217296D0 (en) Method of treatment and/or prevention
GB2499253B (en) Heater and method of operation therefor
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
SMT201800604T1 (it) Composti per il trattamento di obesita' e metodi di uso degli stessi
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
EP2704702A4 (en) COMPOSITION AND METHOD OF TREATING DIABETES
IL239309A0 (en) Methods for the treatment and prevention of respiratory conditions
PL2936151T3 (pl) Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
PL2970463T3 (pl) Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
IL238165A0 (en) Methods for the detection of compounds for the treatment of depression and other related diseases
ZA201408065B (en) Compositions and methods for the treatment of diabetes
IL238331A0 (en) A method for treating type I and type II diabetes
PL2864417T3 (pl) Polimer i sposób zastosowania
ZA201404738B (en) Treatment of type i and type ii diabetes
GB201207907D0 (en) Treatment of depression
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment